Telix Pharmaceuticals Limited [ASX:TLX] share price and news 2022

Company Description

Telix Pharmaceuticals Limited (TLX) is a Melbourne-headquartered oncology company that is developing a pipeline of ‘molecularly targeted radiation’, or ‘MTR’, products for unmet needs in cancer care. TLX is developing a portfolio of clinical-stage oncology products that address unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Telix Pharmaceuticals Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.telixpharma.com.

This a small cap company with market cap of 1084 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 13.7 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how tlx dividend grows in the recent years.

No data